1. Scrip
  2. >>R&D

Nothing Is Undruggable: Novartis' Bradner On CAR-T, CRISPR & DNA Libraries

 
• By Sten Stovall

The head of Novartis' early drug discovery engine NIBR has a zealous sense of mission and says he is being given the resources and talent to accomplish it. "Nothing is undruggable," is his premise.

James Bradner, President of the Novartis Institutes for BioMedical Research (NIBR)
James Bradner, President, Novartis Institutes for BioMedical Research (NIBR) • Source: Novartis AG

Moderation isn't the first word that comes to mind when hearing James Bradner describe his ambitions for the Novartis Institutes for BioMedical Research, which he has headed since March 2016. "I came to lead NIBR to make NIBR the most impactful and most productive biomedical research institute in the world. I’m very excited about having the opportunity to reshape NIBR for the future," he said, outlining his mission.

Bradner's remit, as underscored in an interview with Scrip and at an R&D update to investors by Novartis AG,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

BIO Notebook: MFN Pricing, Next-Gen Obesity R&D, FDA’s Rare Disease Hub & Reaction To Review Program

 
• By Sarah Karlin-Smith, Mandy Jackson, and Alaric DeArment

Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.